NLRP3 and systemic sclerosis: Recent studies have reported significant protective effects resulting from suppression of NLRP3 inflammasome activation in liver fibrosis, systemic sclerosis, systemic lupus erythematosus, systemic sclerosis, diabetes, inflammasome-related eye disease, inflammatory bowel disease, rheumatoid arthritis, and CNS diseases (Zhou et al., 2016; Alegre et al., 2017; Rovira-Llopis et al., 2018; Shen et al., 2018; Yerramothu et al., 2018; Chen et al., 2019a).